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Angiogenesis is a process by which new blood vessels are formed from the pre-existing vasculature, and
it is a key process that leads to tumour development. Some studies have recognized phenolic compounds
as chemopreventive agents; ﬂavonoids, in particular, seem to suppress the growth of tumor cells modify-
ing the cell cycle. Herein, the antiangiogenic activity of Roman chamomile (Chamaemelum nobile L.)
extracts (methanolic extract and infusion) and the main phenolic compounds present (apigenin, apigenin-
7-O-glucoside, caﬀeic acid, chlorogenic acid, luteolin, and luteolin-7-O-glucoside) was evaluated
through enzymatic assays using the tyrosine kinase intracellular domain of the Vascular Endothelium
Growth Factor Receptor-2 (VEGFR-2), which is a transmembrane receptor expressed fundamentally in
endothelial cells involved in angiogenesis, and molecular modelling studies. The methanolic extract
showed a lower IC50 value (concentration that provided 50% of VEGFR-2 inhibition) than the infusion, 269
and 301 μg mL−1, respectively. Regarding phenolic compounds, luteolin and apigenin showed the highest
capacity to inhibit the phosphorylation of VEGFR-2, leading us to believe that these compounds are
involved in the activity revealed by the methanolic extract.
1. Introduction
Angiogenesis is a process by which new blood vessels are
formed from the pre-existing vasculature, developing a hemo-
vascular network.1 It is tightly controlled by a balance of angio-
genesis factors and inhibitors, occurring in the embryonic
development, wound healing and the female reproductive
cycle. Angiogenic diseases result from new blood vessels
growing either excessively (e.g. cancer, diabetic retinopathy
and psoriasis) or insuﬃciently (e.g. chronic wounds and
ischaemic heart disease).1,2
During angiogenesis, endothelial cells degrade the base-
ment membrane, migrate into the surrounding intercellular
matrix, proliferate to form new blood vessels, and diﬀerentiate
into contiguous tubular sprouts, which subsequently form
functional capillary loops. Such cellular events are mediated
by various intracellular signal transduction pathways.3,4 Angio-
genesis happens in the body all the time. It occurs through a
so-called angiogenesis “cascade” which involves a series of
biochemical steps by which cells make and secrete molecules
that initiate the growth of capillaries. After the process is over,
certain other molecular “factors” turn oﬀ the angiogenesis
process. Cancer cells use this normal process for another
purpose, creating an imbalance of angiogenesis activators that
overrides the inhibitors and gives the nearby tumour ready
access to a blood supply.5 This explains why angiogenesis is
essential for the growth, progression, and metastasis of solid
tumours.6
In the mentioned pathophysiological processes, excessive
angiogenesis occurs when diseased cells produce abnormally
large amounts of angiogenesis factors [e.g. vascular endo-
thelial growth factor (VEGF), fibroblast growth factor (FGF)-2
and hepatocyte growth factor], overcoming the eﬀects of
natural angiogenesis inhibitors (e.g. angiostatin, endostatin
and thrombospondin).1
VEGF is a secreted growth factor by tumor cells that plays a
critical role in angiogenesis; low oxygen tension dramatically
induces the expression of this major angiogenic factor.7 Its
biological eﬀects are mediated by two receptor tyrosine
kinases namely VEGFR-1 (fms-like tyrosine kinase, Flt-1) and
VEGFR-2 (kinase-insert domain-containing receptor, KDR),
which diﬀer considerably in their signalling characteristics.8,9
Although increasing evidence indicates that angiogenesis is a
highly sophisticated and coordinated process, the activation of
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the VEGF/VEGFR pathway remains the key modulator of angio-
genesis.10 Furthermore, VEGF is the leading angiogenic factor
involved in tumoral angiogenesis.7,9
Of the primary receptors, VEGFR-2 is thought to mediate
the majority of tumor angiogenic eﬀects (Fig. 1a). Current
clinical treatments against tumor antiangiogenesis that target
VEGFR-2 include: monoclonal antibodies (e.g. bevacizumab)
that target the VEGFR-2 extracellular VEGF binding domain
and small tyrosine kinase inhibitors (TKIs) that target the
VEGFR-2 intracellular tyrosine kinase domain (Fig. 1b). TKIs
act by binding to the ATP binding pocket and to the adjacent
pockets thus preventing the phosphorylation of this intracellu-
lar domain (e.g., sunitinib, sorafenib, ZD6474, erlotinib or tha-
lidomide) and blocking the angiogenic signaling pathway
(Fig. 1c), lowering blood tumoral irrigation, and improving
chemotherapy distribution.9
Several polyphenolic compounds are recognized as cancer
chemopreventive agents. Flavonoids are especially well known
to suppress tumor cell growth via cell-cycle arrest and by the
induction of apoptosis in several tumor cell lines.11,12 More-
over, flavonoids namely genistein inhibit endothelial cell cul-
tures on collagen gels.13 The antiangiogenic eﬀect of apigenin
on tumor cells was also reported and related to a reduction in
the expression of VEGF.12
Other plant-derived anticancer drugs (e.g. Taxol®, campto-
thecin and combretastatin) proved to be antiangiogenic.
In traditional Chinese medicine, many herbs are used in the
treatment of angiogenic diseases such as chronic wounds and
rheumatoid arthritis.1 Furthermore, it has been reported that
drinking green tea could inhibit VEGF-induced angiogenesis
in vivo.5
In a previous study, we reported the antitumor activity of
Roman chamomile (Chamaemelum nobile L.) methanolic
extract and infusion in five diﬀerent human tumour cells (non-
small cell lung cancer, breast, colon, cervical and hepatocellu-
lar carcinomas). Furthermore, flavonoids such as flavonols
and flavones, phenolic acids and derivatives were found in this
wild herb.14 In the present work, the antiangiogenic activity of
Roman chamomile (Chamaemelum nobile L.) extracts (metha-
nolic extract and infusion) and main phenolic compounds
(apigenin, apigenin-7-O-glucoside, caﬀeic acid, chlorogenic
acid, luteolin, and luteolin-7-O-glucoside) were evaluated
through enzymatic assays using the tyrosine kinase intracellu-
lar domain of VEGFR-2. To better understand the inhibition
phosphorylation mechanism of the tyrosine kinase receptor by
luteolin, apigenin and apigenin-7-O-glucoside, docking studies
were performed.
2. Materials and methods
2.1 Biological material and sample preparation
C. nobile was gathered during the flowering season (June–July
2010) from wild populations located in grasslands in Bragança
(Trás-os-Montes, Northeastern Portugal). Samples consist of
pieces of about 8 cm, corresponding to terminal soft leafy
stems and inflorescences with flowers fully open and func-
tional, picked up in plants randomly selected in a meadow of
about a hectare. The plant material was put together in a
single sample for analysis. Voucher specimens are deposited
in the Herbarium of the Escola Superior Agrária de Bragança
(BRESA). The sample was lyophilized (FreeZone 4.5, Labconco,
Kansas, USA), reduced to a fine dried powder (20 mesh) and
mixed to obtain a homogenate sample.
A methanolic extract was prepared from the lyophilized
plant material. The sample (1 g) was extracted by stirring with
25 mL of methanol (25 °C at 150 rpm) for 1 h and sub-
sequently filtered through Whatman No. 4 paper. The residue
was then extracted with 25 mL of methanol (25 °C at 150 rpm)
for 1 h. The combined methanolic extracts were evaporated at
40 °C (rotary evaporator Büchi R-210) to dryness and re-dis-
solved in DMSO to a final concentration of 400 µg mL−1.
Fig. 1 (a) Main angiogenesis signaling pathways mediated by VEGFR-2; (b) X-ray crystal structure of the VEGFR-2 intracellular tyrosine kinase
domain (PDB: 2XIR), co-crystallized with a TKI; (c) detailed representation of the ATP binding pocket and adjacent binding pockets showing the main
interactions between VEGF-2 and the TKI (PDB: 2XIR).
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An infusion was also prepared from the lyophilized plant
material. The sample (1 g) was added to 200 mL of boiling dis-
tilled water and left to stand at room temperature for 5 min,
and then filtered under reduced pressure. The obtained infu-
sion was frozen, lyophilized and re-dissolved in DMSO to a
final concentration of 400 µg mL−1.
2.2. Phenolic compounds
Apigenin, apigenin-7-O-glucoside, caﬀeic acid, chlorogenic
acid, luteolin, and luteolin-7-O-glucoside were from Extrasynth-
ese (Genay, France). Each phenolic compound was dissolved in
DMSO to a final concentration of 40 µg mL−1.
2.3. VEGFR-2 enzymatic inhibition assay
C. nobile methanolic extract and infusion, and the pure pheno-
lic compounds were assessed for VEGFR-2 inhibition activity
using the Z′-LYTE-Tyr1 Peptide assay kit (Invitrogen, Cat.
PV3190) according to the procedures recommended by the
manufacturer.15 Briefly, assays were performed in a total of
20 µL in 384-well plates using fluorescence resonance energy
transfer technology. A Tyr1 substrate (coumarin-fluorescein
double-labeled peptide) at 1 µM was incubated for 1 h with
4 µg mL−1 VEGFR-2, 50 μM ATP and the C. nobile methanolic
extract/infusion (400 at 6.25 µg mL−1) or the pure phenolic
compounds (40 at 0.04 µg mL−1) at room temperature in
50 mM Hepes/NaOH (pH 7.5), 10 mM MgCl2, 2 mM MnCl2,
2.5 mM DTT, 0.1 mM orthovanadate, and 0.01% bovine serum
albumin. The wells were incubated at 25 °C for 1 h and 5 µL
development reagents were added to each well. After a second
incubation of 1 h a stop reagent was added to each well. Using
a Biotek FLX800 micro-plate the fluorescence was read at
445 nm and 520 nm (excitation 400 nm), and Gen5™ Software
was used for data analysis. Genistein (Extrasynthese, Genay,
France) was used as positive control.
The assays were performed in triplicate and the results were
expressed as mean values ± standard deviation (SD). The
results were analyzed using a Student’s t-test with α = 0.05, to
determine the significant diﬀerence among the two extracts.
For the phenolic compounds, the analysis was performed
using one-way analysis of variance (ANOVA) followed by
Tukey’s HSD test with α = 0.05. These treatments were carried
out using the SPSS v. 22.0 program.
2.4 Docking simulations using AutoDockVina
The 2D structure of the compounds apigenin, apigenin-7-O-
glucoside, luteolin and luteolin-7-O-glucoside was constructed
using the ACD/ChemSketch Freeware 12.0 software. Open
Babel16 was used to convert compounds from 2D to 3D and
they were saved in the pdb format.
A VEGFR-2 crystal structure (PDB: 2XIR) was extracted from
the Protein Data Bank (PDB) (http://www.rcsb.org). The co-crys-
tallized ligand was extracted from the PDB file, and AutoDock-
Tools17 was used to assign polar hydrogens and Gasteiger
charges to the compounds and VEGFR-2 protein. All structures
were saved in the PDBQT file format required to use AutoDock-
Vina.18 AutodockVina was used to perform docking in an area
of 30 Å × 30 Å × 30 Å, centered on the co-crystallized ligand.
The docking simulations were performed on a cluster of 6
AMD Opteron 6128 8 core 2.0 GHz by using MOLA software.19
All figures with structure representations were prepared using
PyMOL (The PyMOL Molecular Graphics System, Version 1.3,
Schrödinger, LLC). Available at: (http://www.pymol.org/). Accessed
on 03 September, 2012.
2.5 Molecular dynamics simulation
The protein preparation wizard from Maestro (Schrodinger,
LLC, Portland, OR) was used to prepare ligand/VEGFR-2 com-
plexes and then used to perform explicit solvent molecular
dynamics (MD) simulations. The parallelized Desmond Mole-
cular Dynamics System v2.2 (D. E. Shaw Research, New York,
NY) and associated analysis tools, available within the Schro-
dinger suite (Schrodinger, LLC, Portland, OR), were used for
this purpose. The protocol used was described by Mukherjee
et al.20
3. Results and discussion
According to previous studies of the authors, Roman chamo-
mile is an equilibrated valuable species rich in carbohydrates
and proteins, and poor in fat, providing tocopherols, caroten-
oids and essential fatty acids (C18:2n6 and C18:3n3). More-
over, the herb and its infusion are a source of phenolic
compounds and organic acids with high bioactive potential.14
Herein, methanolic extract, infusion and phenolic compounds
of Roman chamomile were evaluated for their ability to inter-
act with the VEGFR-2 kinase domain, using an enzymatic
(fluorescence resonance energy transfer) FRET-based assay.
The results are shown in Table 1.
The methanolic extract showed a lower IC50 value than the
infusion, 269 and 301 μg mL−1, respectively. These results are
in agreement with the higher phenolic compound amount,
antioxidant and antitumor activities also previously reported
for the methanolic extract.14
Table 1 VEGFR-2 inhibition activity of Chamaemelum nobile extracts
and phenolic compounds (mean ± SD)
Chamaemelum nobile VEGFR-2 IC50, μg mL−1
Methanolic extract 269.26 ± 8.74
Infusion 301.09 ± 13.07
Student’s t test; p-value <0.001
Phenolic compound VEGFR-2 IC50, μg mL−1
Luteolin 0.60 ± 0.03c*
Apigenin 1.29 ± 0.07b
Apigenin-7-O-glucoside 19.21 ± 1.58a
Luteolin-7-O-glucoside >40
Caﬀeic acid >40
Chlorogenic acid >40
Genistein 1.04 ± 0.06
IC50-concentration that provided 50% of VEGFR-2 inhibition.
*Diﬀerent letters mean significant diﬀerences between compounds
(p < 0.05).
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Regarding individual molecules, apigenin, apigenin-7-O-
glucoside, caﬀeic acid, chlorogenic acid, luteolin and luteolin-
7-O-glucoside were chosen because these compounds were the
ones used to quantify all the phenolic compounds identified
in Roman chamomile.14 Phenolic acids (caﬀeic and chloro-
genic acids) and luteolin-7-O-glucoside did not show the
VEGFR-2 inhibition activity (IC50 values higher than 40 µg mL
−1),
whereas apigenin-7-O-glucoside showed VEGFR-2 inhibition
activity with the IC50 value = 19.21 µg mL
−1. A drastic increase
in the VEGFR-2 inhibition activity was observed for the corres-
ponding aglycones (compounds without the glycosyl group) of
the mentioned flavonoids: luteolin and apigenin (IC50 values =
0.60 and 1.29 µg mL−1, respectively). The active concen-
trations, corresponding to the last IC50 values, are easily pro-
vided by the Roman chamomile infusion, which contains 8.42
µg mL−1 and 9.28 µg mL−1 of luteolin and apigenin derivatives
(compounds with glycosyl groups: luteolin-7-O-glucoside and
apigenin-7-O-glucoside), respectively (values calculated from
the ones reported previously by the authors and taking into
account the extraction yields).14 It should be highlighted
that the methanolic extract prepared from the herb would
provide even higher amounts of those derivatives (21.31 and
13.50 µg mL−1, respectively14).
The possible VEGFR-2 inhibition mechanism of luteolin,
apigenin and apigenin-7-O-glucoside (Fig. 2) was predicted
using docking tools. A careful analysis of the predicted
docking poses showed that apigenin and luteolin probably
interact with the VEGFR-2 ATP binding site with a similar
binding pose, stabilized by three predicted hydrogen bonds
(Fig. 3): one H-bond between the CYS919 backbone and the
carbonyl group at position 3 of the benzopyrone moiety; a
second H-bond between the CYS919 backbone and the
hydroxyl group at position 5 of the benzopyrone moiety; and a
third H-bond between the amino group of the LYS868 side
chain and the hydroxyl group at position 4 of the benzene
ring. The higher VEGFR-2 inhibition capacity of luteolin com-
pared to apigenin can probably be explained by the better
occupation of the ATP binding site, accomplished by the lutein
extra hydroxyl group occupation of a small pocket located
inside the structure shown in Fig. 3. Furthermore, comparing
the docking poses of apigenin and apigenin-7-O-glucoside, it
was possible to observe that the presence of the glucoside
moiety shifts the compound slightly away from the ATP
binding site. This shift probably weakens the described
H-bonds, explaining the lower VEGFR-2 inhibition capacity of
apigenin-7-O-glucoside.
Moreover, the inability of AutodockVina to predict the
binding pose of luteolin-7-O-glucoside similar to luteolin, api-
genin and apigenin-7-O-glucoside seems to indicate that luteo-
lin-7-O-glucoside probably cannot interact with the ATP
binding site. This was experimentally proved by the high IC50
value obtained in the enzymatic assay (>100 µM).
MD (Molecular Dynamics) simulations were performed
using the most active compounds, luteolin and apigenin, to
verify whether both the predicted docking poses remain stable
in a more physiologically relevant setting. The docking poses
of both complexes were the starting points for 5 ns MD simu-
lations, and the overall stability of each MD simulation was
evaluated by plotting the receptor backbone (VEGFR-2) and
ligands’ RMSD (Root Mean Square Deviation) as a function of
time (Fig. 4).
After small adjustments in the first ns of the MD simu-
lation, both apigenin and luteolin structures remained stable
during the MD simulation with an average RMSD of 0.37 and
0.57 Å, respectively (Fig. 4). This is an indication that the pre-
dicted docking pose is reliable and is probably close to the
experimental VEGFR-2 binding pose. In both MD simulations,
the RMSD values for the VEGFR-2 backbone structure were
also analyzed and it was observed that, after a normal adjust-
ment of around 2 ns, the RMSD values also remained stable
during rest of the MD simulation. This is the expected MD
simulation behavior of the protein backbone indicating that
the VEGFR-2 structure used is suitable for this type of mole-
cular modeling study.
Fig. 2 Chemical structures of luteolin, apigenin and apigenin-7-O-
glucoside.
Fig. 3 Surface representation of the VEGFR-2 ATP binding site docked
with apigenin (green line), luteolin (blue line) and apigenin-7-O-gluco-
side (magenta line). Apigenin and luteolin hydrogen bonds are rep-
resented as yellow dashes, and apigenin-7-O-glucoside hydrogen bonds
as red dashes.
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In general the MD simulations performed gave us further
assurance that the predicted docking pose probably corre-
sponds closely to the experimental binding pose although this
can only be completely established by the elucidation of the
VEGFR-2/apigenin or VEGFR2/luteolin complex structures,
usually performed by X-ray crystallography.
The antiangiogenic eﬀect of apigenin on tumor cells has
already been reported but related to the reduction in the
expression of VEGF12 and not to the inhibition of VEGFR
activity, so it is demonstrated in the present work. Regarding
luteolin, as far as we know this is the first report on antiangio-
genic activity, and only its anticarcinogenic eﬀects mainly by
induction of apoptosis and cell cycle arrest by the action on
critical molecular targets for cell survival such as p53, p21,
cyclin dependent kinases and caspases in liver21 and non-
small cell lung22 cancer cells are reported.
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